story of the week
Pembrolizumab Plus Chemotherapy vs Chemotherapy for Untreated Advanced Pleural Mesothelioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Lancet 2023 Nov 03;[EPub Ahead of Print], Q Chu, F Perrone, L Greillier, W Tu, MC Piccirillo, F Grosso, G Lo Russo, M Florescu, M Mencoboni, A Morabito, FL Cecere, GL Ceresoli, DE Dawe, PA Zucali, M Pagano, JR Goffin, ML Sanchez, C Gridelli, G Zalcman, X Quantin, V Westeel, P Gargiulo, S Delfanti, D Tu, CW Lee, N Leighl, J Sederias, P Brown-Walker, Y Luo, S Lantuejoul, MS Tsao, A Scherpereel, P Bradbury, SA Laurie, L SeymourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.